Loading people...
Andy Harrison is a highly respected Managing Partner at Section 32, a prominent venture capital firm. He is known for his extensive experience in healthcare, life sciences, and technology investments, having previously held key roles at Google Ventures and Venrock.
Andy Harrison primarily invests in groundbreaking companies within the healthcare, life sciences, and technology sectors. His focus areas include biotechnology, digital health, medical devices, and the application of artificial intelligence to solve complex health challenges.
Andy Harrison works as a Managing Partner at Section 32, a leading venture capital firm. Section 32 is dedicated to investing in transformative companies across healthcare, life sciences, and technology.
Andy Harrison is a chemical engineer turned venture capitalist who specializes in early-stage deep tech investments across multiple emerging scientific sectors. He established his foundational technical expertise through rigorous academic training, earning a Master of Engineering in Chemical and Biomolecular Engineering from Cornell University. Prior to his graduate studies, Harrison completed a Bachelor of Engineering in Chemical and Biomolecular Engineering at McGill University, giving him dual degrees in the discipline. Transitioning from traditional engineering into the venture capital sector, he now utilizes his advanced scientific background to bridge the gap between complex technical evaluation and institutional investment strategy. His primary sector focus targets emerging companies operating at the intersection of hardware development, biotechnology, and advanced materials. Ultimately, Harrison focuses on deploying capital into highly technical, early-stage startups where his specialized knowledge assesses deep tech viability.
Andy Harrison stands as a pivotal figure in the venture capital landscape, serving as a Managing Partner at Section 32. At this leading firm, co-founded by Google Ventures founder Bill Maris, Harrison plays a crucial role in identifying and nurturing groundbreaking companies that are set to redefine the future of healthcare, life sciences, and technology. His leadership at Section 32 reinforces the firm's commitment to investing in disruptive innovations that address significant global challenges and improve human well-being.
Harrison's investment focus is broad yet deeply specialized, encompassing areas such as biotechnology, digital health, medical devices, and the application of artificial intelligence in healthcare. He seeks out visionary entrepreneurs and companies developing cutting-edge solutions, from novel therapeutics and diagnostics to advanced health tech platforms. His strategic insights help guide these ventures through critical growth stages, leveraging his extensive network and industry expertise to accelerate their success. Section 32, under Harrison's guidance, is particularly interested in companies that demonstrate strong scientific foundations, clear market potential, and the ability to scale their impact.
Before joining Section 32, Andy Harrison built an impressive career marked by significant contributions across both operational and investment roles. He was a key member of the Google Ventures (GV) team, where he worked alongside Bill Maris and led numerous successful investments in the life sciences and healthcare sectors. His tenure at GV solidified his reputation as a discerning investor with a keen eye for transformative technologies. Prior to GV, Harrison honed his investment acumen at Venrock, another top-tier venture capital firm, where he continued to focus on healthcare opportunities. His earlier career also includes valuable operational experience at Genentech, a pioneering biotechnology company. This blend of hands-on industry experience and deep investment expertise provides him with a unique perspective, enabling him to thoroughly evaluate complex scientific and business models.
Throughout his career, Andy Harrison has been associated with numerous impactful investments that have gone on to achieve significant milestones. While specific investment details often remain proprietary, companies like Freenome, GRAIL, Guardant Health, Invitae, and Sana Biotechnology represent the caliber of innovative firms he has supported. These companies are at the forefront of developing advanced diagnostics, precision medicine, and novel therapies, reflecting Harrison's dedication to backing ventures that promise substantial societal benefit and strong financial returns.
As a Managing Partner at Section 32, Andy Harrison continues to shape the future of healthcare and technology investment. His strategic vision, combined with a profound understanding of scientific innovation and market dynamics, positions him as a leading voice in the venture capital community. He remains committed to empowering entrepreneurs who are building the next generation of industry-leading companies, driving progress and delivering tangible value across the globe.
